DANIEL B. SOLAND - 29 May 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Director
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
29 May 2024
Net transactions value
$0
Form type
4
Filing time
31 May 2024, 18:00:10 UTC
Previous filing
03 Aug 2023
Next filing
02 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +6,652 +24% 34,654 29 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -6,652 -100% $0.000000* 0 29 May 2024 Common Stock 6,652 Direct F1, F2
transaction ACAD Director Stock Options (Right to Buy) Award $0 +15,959 $0.000000 15,959 29 May 2024 Common Stock 15,959 $14.62 Direct F3
transaction ACAD Restricted Stock Units Award $0 +9,387 $0.000000 9,387 29 May 2024 Common Stock 9,387 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2 The restricted stock units vested in full on May 29, 2024, the date on which an annual meeting of stockholders was held.
F3 The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4 The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.